"The U.S. Food and Drug Administration today cleared a new screening test that predicts a patient's risk of future coronary heart disease (CHD) events, such as heart attacks.
FDA cleared the test for use in all adults with no history of hear"...
Ancobon is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
DOSAGE AND ADMINISTRATION
The usual dosage of Ancobon is 50 to 150 mg/kg/day administered in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided if the capsules are given a few at a time over a 15- minute period. If the BUN or the serum creatinine is elevated, or if there are other signs of renal impairment, the initial dose should be at the lower level (see WARNINGS).
Ancobon should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Ancobon (See Microbiology).
Capsules, 250 mg (gray and green), imprinted ANCOBON® 250 ICN, bottles of 100 (NDC 0187-3554- 10). Capsules, 500 mg (gray and white), imprinted ANCOBON® 500 ICN, bottles of 100 (NDC 0187- 3555-10).
Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F).
Manufactured in Canada by: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7. Canada. Distributed by: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA. 1-800-321-4576. Revised: Feb 2013This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/18/2016
Additional Ancobon Information
Ancobon - User Reviews
Ancobon User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.